NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222 at the 65th American Society of Hematology Annual Meeting NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222

NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting

NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of Directors LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today...

NovalGen announces one oral and two poster presentations at the American Society of Hematology Annual Meeting -Updated clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL -- Pre-clinical data for a first in class half-life extended T Cell engager...

NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting - First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL - Early data demonstrates promising efficacy with a predictable and...